Loading...
Loading...
In a research report published earlier today, Morgan Stanley commented on the recent Pfizer
PFE Emerging Markets & Established Products meeting.
According to Morgan Stanley, “On Friday March 30th, we met with David Simmons, President of Emerging Markets (
EM) and Established Products (
EP), and Susan Silverman, Head of LatAm. We found both to be quite impressive and direct. EM and EP are each approximately $10 billion operations (each 15% of total Pfizer revenue). Four takeaways were: 1) we expect Pfizer to retain EP, 2) generics M&A likely to be niche, 3) U.S. Lipitor strategy is working, and 4) EM should accelerate.”
Morgan Stanley maintains its Overweight rating on Pfizer, which closed Friday at $22.66.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in